Studies Validate IL-17 as Hidradenitis Suppurativa Drug Target

Two phase 3 studies with the IL-17 inhibitor bimekizumab for moderate-to-severe hidradenitis suppurativa generate clinically meaningful results, researchers report.

Related Keywords

Boston ,Massachusetts ,United States ,American ,Christopherj Sayed ,Alexab Kimball , ,Pfizer ,American Academy Of Dermatology ,Beth Israel Deaconess Medical Center ,Research Session ,Harvard Medical School ,University Of North Carolina ,Novartis ,American Academy ,Hidradenitis Suppurativa Clinical Response ,Dermatology Life Quality Index ,North Carolina ,Chapel Hill ,Skin And Soft Tissue Infection ,Humanized Monoclonal Antibody ,Evacizumab ,Rastuzumab ,Hidradenitis Suppurativa ,Abscess ,Clinical Research ,Clinical Trials ,Linical Studies ,Nodule ,Quality Of Life ,Pol ,Ealth Related Quality Of Life ,Rqol ,Echocardiography ,Echocardiogram ,Echo ,Interleukins ,Monoclonal Antibody ,Etuximab ,Ituximab ,Spain ,Antibiotics ,